Gene Therapy Helps Some Blind Patients Detect Objects in Landmark Optogenetic Trial

Researchers have reported encouraging results from an experimental gene-therapy approach designed to restore aspects of vision in people with advanced retinitis pigmentosa, an inherited retinal disorder that can eventually cause blindness.

The treatment uses an optogenetic approach in which surviving retinal ganglion cells are genetically modified to become sensitive to light. Patients then use specially designed goggles that stimulate these cells and convert visual information into light signals.

The clinical study involved 10 people with advanced disease. Researchers reported that the treatment was considered safe and that six participants experienced a clinically meaningful improvement in light sensitivity. Some patients were also able to perform tasks such as detecting or locating objects.

The treatment does not currently restore normal high-resolution vision or replace the complex visual processing performed by a healthy retina. Nevertheless, the results demonstrate that optogenetic therapy can potentially provide useful visual information even when significant retinal degeneration has already occurred.

The development is particularly important for neurology and neuro-ophthalmology because it demonstrates how gene therapy can interact with neural circuits to restore aspects of lost sensory function.